Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma

European Journal of Cancer

Volumn 36, Issue 3, 2000, Pages 363-367

  Bower, M ^a   Stern, S ^a   Fife, K ^a   Nelson, M ^a   Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

AIDS; Chemotherapy; HIV; Non Hodgkin's lymphoma

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BLEOMYCIN; CD4 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; ISONIAZID; METHOTREXATE; PREDNISOLONE; PROTEINASE INHIBITOR; PYRIDOXINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; GIARDIASIS; HERPES; HISTOLOGY; HUMAN; MENINX DISORDER; MORTALITY; MUCOSA INFLAMMATION; MYCOBACTERIOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETINITIS; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS;

EID: 0033993876     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00260-9     Document Type: Article

References (14)

1. Kaplan L. Clinical management of human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Natl Cancer Inst Monogr 1998, 23, 101-105.
2. Kaplan L, Abrams D, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. J Am Med Assoc 1989, 261, 719-724.
3. Levine A, Sullivan-Halley J, Pike M, et al. Human immunodeficiency virus-related lymphoma: prognostic factors predicitive of survival. Cancer 1991, 68, 2466-2472.
4. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998, 16, 3601-3606.
5. The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329, 987-994.
6. Kaplan LD, Straus DJ, Testa MA, et al. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997, 336, 1641-1648.
7. Bower M, Brock C, Gulliford T, O'Reilly SM, Smith DB, Newlands ES. A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma. Cancer Chemother Pharmacol 1995, 38, 106-109.
8. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
9. Peto R, Pike M, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer 1977, 35, 1-39.
10. Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunodeficiency virus-related lymphoma treatment with intensive chemotherapy. Am J Med 1993, 95, 188-196.
11. Vaccher E, Spina M, Santarossa S, et al. Concomitant CHOP chemotherapy and highly active antiretroviral therapy (HAART) in patients with HIV related non-Hodgkin's lymphoma. 12th World AIDS Conference. Geneva, 1998, Abstract 22289.
12. Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV and HTLV-1 related non Hodgkin's lymphoma. Blood 1993, 81, 2810-2815.
13. Sparano JA, Wiernik PH, Hu X, et al. Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV associated non-Hodgkin's lymphoma. J Clin Oncol 1996, 14, 3026-3035.
14. Sparano JA, Wiernik PH, Hu X, Sarta H, Henry DH, Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 1998, 15, 50-57.